EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease

Andrew R Roney, Dupre Orr, Armeen Barghi, Sureya Hussani, Vivy Cusumano, Berkeley N Limketkai, Jenny S Sauk

Digestive Diseases and Sciences · 2026-08 · 71 (8) · 3583-3593

DOI: 10.1007/s10620-026-09797-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 24.03.2026. Verfasst von Andrew R Roney und 6 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Infliximab, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor-alphaInfliximabInflammatory Bowel DiseasesGastrointestinal AgentsHumansFemaleRetrospective StudiesMaleAdultMiddle AgedTreatment OutcomeTime FactorsLongitudinal Studies

Stichwörter der Autor:innen

Adverse eventsAnti-tumor necrosis factorInflammatory bowel diseaseLong-termSafety

Substanzen

Tumor Necrosis Factor-alphaInfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. jsauk@mednet.ucla.edu.

Zitieren

APA

Roney, A. R., Orr, D., Barghi, A., Hussani, S., Cusumano, V., Limketkai, B. N., & Sauk, J. S. (2026). Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 71(8), 3583-3593. https://doi.org/10.1007/s10620-026-09797-7

Vancouver

Roney AR, Orr D, Barghi A, Hussani S, Cusumano V, Limketkai BN, et al. Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease. Digestive Diseases and Sciences. 2026;71(8):3583-3593. doi:10.1007/s10620-026-09797-7

BibTeX
@article{Roney2026,
  author = {Roney, Andrew R and Orr, Dupre and Barghi, Armeen and Hussani, Sureya and Cusumano, Vivy and Limketkai, Berkeley N and Sauk, Jenny S},
  title = {Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  volume = {71},
  number = {8},
  pages = {3583--3593},
  doi = {10.1007/s10620-026-09797-7}
}
Kostenlos starten →